Understanding Immunity and Vaccination

Challenges in Vaccine Development: The Case of HIV

While many vaccines have been successful, some pathogens present extraordinary biological hurdles. HIV is perhaps the most significant challenge in vaccine research.

A major obstacle is a phenomenon known as immunodominance. This occurs when the immune system focuses its response on the most "conspicuous" or visible parts of the virus. In the case of HIV, these parts act as decoys; they are highly variable and change rapidly from one strain to the next, meaning antibodies produced against them are ineffective against different subtypes.

To create an effective vaccine, researchers aim to target conserved epitopes—specific parts of the virus that are essential to its survival and mechanism, making them difficult for the virus to mutate. These critical sites are often difficult for the immune system to "see" because they are hidden by a "cloak" of sugar molecules known as glycans.

One promising approach in recent years has been the development of the SAVO01 vaccine. This vaccine uses genetically modified, killed whole HIV-1 particles that are unable to infect human cells. It has shown potential in stimulating broadly neutralizing antibodies that can cover multiple different strains of the virus.

Human Papillomavirus (HPV) Vaccines

Unlike the complexities of HIV, vaccines for the Human Papillomavirus (HPV) have provided clear pathways for cancer prevention. HPV is a virus associated with genital warts and various cancers, including cervical, anal, and throat cancers.

In Canada, two primary vaccines are available:

• Cervarix (HPV2): Protects against two types of HPV that cause approximately 70% of cervical cancers and 80% of anal cancers.
• Gardasil 9 (HPV9): Provides broader protection by targeting the same two strains as Cervarix, plus five additional strains. This expanded coverage protects against an additional 15-20% of cervical cancers and approximately 90% of genital warts.

Coronaviruses and SARS-CoV-2

Coronaviruses (CoVs) are enveloped, positive-sense single-stranded RNA (ssRNA+) viruses. Their structure is defined by four primary proteins:

1. Spike (S): The protein used for cell entry.
2. Membrane (M): Provides structural integrity.
3. Envelope (E): Involved in viral assembly.
4. Nucleocapsid (N): Interacts with the viral RNA to form the core.

Vaccination Protocols for COVID-19

To combat SARS-CoV-2, various technological platforms have been deployed, including mRNA and protein subunit vaccines. The administration of these vaccines typically follows a structured protocol:

• Primary Series: This is the initial set of doses required to establish a strong immune response. For most people using mRNA vaccines (like Pfizer or Moderna), this consists of two doses administered eight weeks apart. However, immunocompromised individuals may require a three-dose primary series.
• Booster Doses: Because immunity can wane over time or be bypassed by new viral variants, booster doses are administered after the primary series to maintain protection against severe disease.

Clinical Note: Eligibility for boosters is often determined by the interval since the last dose. For individuals aged five and older, a booster is typically recommended at a minimum interval of three months, or a standard interval of six months.